The outcomes of various clinical trials concerning ADCs, including DESTINY Breast04 and TROPICS02, provide solution to the treatment dilemma faced in HER2-negative breast cancer.7,27 Moreover, the potential of T-DXd in treating HER2-low MBC presents encouraging possibilities for tailored therapeutic strategies aimed at addressing HER2-low breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.